klebsiella pneumoniae bioconjugate vaccine

The Klebsiella pneumoniae bioconjugate vaccine is a preclinical-stage prophylactic candidate being developed by Omniose to prevent infections caused by the Gram-negative bacterium *Klebsiella pneumoniae*, including multi-drug resistant (MDR) strains. The vaccine is produced using Omniose's proprietary Enzyme-mediated Conjugation (EMC) platform, which utilizes a specialized glycosyltransferase (such as PglB) to site-specifically attach bacterial capsular polysaccharides to carrier proteins within an engineered *E. coli* host. This bioconjugation process is designed to produce more homogenous and immunogenic vaccines compared to traditional chemical conjugation methods, aiming to elicit high titers of opsonophagocytic antibodies against the pathogen's capsule.

Other names

Klebsiella pneumoniae vaccineOmniose Klebsiella vaccine